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Abstract: MRI offers high spatial resolution with excellent
tissue penetration but it has limited sensitivity and the
commonly administered contrast agents lack specificity. In
this study, two sets of iron oxide nanoparticles (IONPs) were
synthesized that were designed to selectively undergo copper-
free click conjugation upon sensing of matrix metalloprotei-
nase (MMP) enzymes, thereby leading to a self-assembled
superparamagnetic nanocluster network with T2 signal en-
hancement properties. For this purpose, IONPs with bioor-
thogonal azide and alkyne surfaces masked by polyethylene
glycol (PEG) layers tethered to CXCR4-targeted peptide
ligands were synthesized and characterized. The IONPs were
tested in vitro and T2 signal enhancements of around 160%
were measured when the IONPs were incubated with cells
expressing MMP2/9 and CXCR4. Simultaneous systemic
administration of the bioorthogonal IONPs in tumor-bearing
mice demonstrated the signal-enhancing ability of these smart
self-assembling nanomaterials.
The early detection of primary tumors and metastases is
a major clinical challenge, and an emerging approach for
targeting imaging agents to tumors is to exploit the changes
that occur within the local tumor microenvironment. The
matrix metalloproteinase (MMP) enzymes MMP2 and
MMP9 have been shown to play an important role in tumor
development and metastasis.[1,2] These MMPs are thus
excellent biomarkers for the development of tumor-targeted
contrast agents.[3]
In biomedical imaging, MRI is a noninvasive imaging
technique that has high spatial resolution and does not
require ionizing radiation.[4] However, MRI suffers from
limited sensitivity[5] and the use of contrast agents is necessary
to increase sensitivity and image contrast in MR scans.[5a,6]
Superparamagnetic IONPs are widely used in MRI owing to
their biocompatible nature and strong effects on T2 and T2*
relaxation.[7] To increase the sensitivity of T2-weighted MRI,
several strategies with NPs have been adopted,[8] however,
fewer examples exist that utilize changes in NP size to achieve
signal amplification in MR scans.[9] Larger iron oxide nano-
particles (IONPs) and magnetic nanoparticle aggregates have
pronounced magnetic properties,[7,9c] but are cleared faster
from the blood pool by the mononuclear phagocyte system.[10]
We have designed two sets of novel IONPs that only form
aggregates within the tumor environment, where self-assem-
bly into larger particles is triggered by cancer-specific MMP
biomarkers. The sensitivity of MRI can thus be enhanced
through both specific tumor targeting and tumor-associated
proteolytic enzyme activity. It is known that magnetic
susceptibility increases when NP aggregates are formed and
this process also increases the r2 relaxivity.
[11] The issue of low
sensitivity is being tackled,[9a,c,12] however, the work has either
not progressed to in vitro or in vivo stages, or the aggregation
process has relied upon electrostatic and non-covalent
interactions.
In this work, we utilized copper-free “click” chemistry to
achieve NP self-assembly and therefore MR T2 signal
amplification both in vitro and in vivo. Rather than relying
on nonspecific processes, we chose to use copper-free click
chemistry[13] to form covalent bonds between the particles.
The strategy of targeting the CXCR4 receptor[14] is crucial and
in preclinical studies, this has shown far superior performance
compared to passive approaches. CXCR4 levels can be
predictive of metastatic potential,[14f, 15] and we demonstrate
that the EPR effect alone is not enough to highlight tumors.
The general concept is presented in Figure 1; these
particles have a surface decorated with peptide ligands that
target them to tumor sites. Their structure also contains
peptide sequences cleavable by the MMP2/9 enzymes over-
expressed in tumors.[3] The cleavage of the protease-specific
peptides exposes either azide or alkyne moieties on the NP
surfaces, thereby allowing the particles to undergo a [3+2]
cycloaddition reaction. This copper-free chemical reaction
leads to self-assembly of the IONPs and the change in particle
distribution has an effect on the relaxivity (r2) of the contrast
agent. The relaxivity is higher after assembly,[11] thus resulting
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in improved contrast in T2-weighted MR images. Further-
more, the IONPs are PEGylated, thus leading to improved
in vivo bioavailability.[16] The targeting ligand incorporated on
the surface of the IONPs is
a cyclopentapeptide with
affinity for the CXCR4
receptor.[17]
Magnetite (Fe3O4) was
chosen as the core material
for the development of the
IONPs[18] and a monodis-
persed population of oleic
acid capped IONPs was
prepared according to
a reported method.[19] The
particles were fully charac-
terized by using standard
techniques (Figures S1,S2
and Data S3 in the Support-
ing Information). In the
next part of the synthetic
strategy, a series of sequen-
tial surface functionaliza-
tions were performed
(Figure 2 and Data S4), and
the reaction sequences
could be monitored by FTIR spectroscopy (Figure S5 and
S6) and 1H NMR spectroscopy (Figure S7).
In the final step, a targeting cyclopeptide directed against
CXCR4 was introduced for specific binding to CXCR4 (to
form 11 and 12), thereby yielding targeted NPs with an
average of 10 targeting peptides per particle. The successful
preparation of the final ligands was assessed by MALDI mass
spectrometry (Figure S8). The simple and repeated chemistry
involved in the final stages of the NP preparation (Figure 2)
enabled the preparation of different controls, for example, 10
and 13 (Figure 3). The final targeted NPs were very similar in
terms of size (Figure 4A) and surface charge (Table S2 in the
Supporting Information), thus suggesting the likelihood of
similar circulation times and biodistribution patterns in vivo.
The proof-of-principle for the design was obtained by
using hydrodynamic size measurements (Figure 4A). The two
families of NPs were mixed in equimolar concentrations and
incubated at 25 8C for 2 h. Hydrodynamic size measurements
were acquired at 0, 15, 30 and 60 mins. The data show that
after an initial size increase, the sizes tended to return to the
original values (proof that no covalent bonds were formed).
However, when the incubation was performed in the presence
of MMP9, the size of the aggregates increased dramatically
over time (6-fold after 15 mins, from 140 nm to 780 nm). The
formation of NP aggregates was further confirmed by TEM
(Figure S9). Relaxivity measurements also confirmed the
presence of the aggregates since the T2 value of the 1:1
mixture of NPs dropped around 60% after 30 mins incubation
with MMP9 (Table S1).
The ability of the NPs to target the CXCR4 receptor was
characterized in vitro by MRI. A CXCR4- and MMP9-
expressing cell line (U87.CD4.CXCR4)[3] was incubated in
the presence of the NPs for different periods of time (15, 30
and 60 mins) in order to find an optimal incubation time
(Figure 4B). The maximum decrease in T2 time was achieved
after 30 mins of incubation with the NPs. When CXCR4-
Figure 1. In vitro and in vivo “clicking” NPs. Two complementary
IONPs were designed to undergo a bioorthogonal reaction after
cleavage by MMP enzymes, which exposes the azide or alkyne moieties
on either set of NPs. MNP=magnetic nanoparticle, PEG=polyethy-
lene glycol.
Figure 2. Sequential surface functionalization of synthesized IONPs. AUA=11-aminoundecanoic acid;
P-PEG7-N3=O-(2-azidoethyl)heptaethylene glycol phosphonooxy-ethyl ester; COGA=cyclooct-1-yn-3-glycolic
acid; 4-APB=4-azidophenacyl bromide; MMP pept=DNP-Pro-Leu-Gly-Met-Trp-Ser-Arg; P-PEG7-N3=O-(2-
azidoethyl)heptaethylene glycol phosphate; CXCR4 pept= cNal-Gly-d-Tyr-Orn[PEG-NH2]-Arg.
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positive cells were incubated with targeted NPs, a large
decrease in T2 was observed (DR2/R2only cells 160%; Fig-
ure 4C). However, when either control nontargeted NPs or
CXCR4-negative cells (U87.CD4) were used, the T2
remained almost unchanged (DR2/R2only cells 16%). If an
inhibitor of CXCR4 (AMD3100)[20] was added into the
incubation media, the signal recovered to intermediate
levels (DR2/R2only cells 60%), thus demonstrating the target-
ing potential of the NPs. To test whether the cells produced
enough MMP enzymes to observe an effect on the T2 signal,
exogenous MMP9 was added into the culture media. The
results were very similar to those obtained without extra
enzyme, thus indicating that the cells secreted enoughMMP2/
9 for the reaction to take place (Figure 4C). Finally, when
control NPs without assembling properties, for example, 13,
were incubated with U87.CD4.CXCR4 cells, the contrast of
the images (DR2/R2only cells 65%) fell somewhere between the
that of the complete targeted NPs and that of the control
nontargeted ones.
Before proceeding to in vivo tests, the level of CXCR4
expression in U87.CD4.CXCR4 tumor xenografts in vivo was
analyzed by Western blot assays. The results confirmed high
levels of CXCR4 expression in these tumors (Figure S10A).
To gauge the maximal tumor signal enhancing capability of
the NPs, they were preassembled in an Eppendorf tube in the
presence of MMP9. This solution was then injected intra-
tumorally into U87.CD4.CXCR4 xenografts implanted in
BALB/c nude mice (Figure S10B). The mice were imaged
before and after injection, and T2-weighted images acquired
from the tumor showed a localized black spot at the injection
site with a global decrease in signal intensity in the tumor of
around 25%.
Next, mice bearing
tumors were intravenously
injected with a mixture of
the two populations of NPs
in the same needle. Results
from mice (n= 3) injected
with targeted IONPs
revealed that the T2 relaxa-
tion time of the entire
tumor had decreased by
approximately 14% at 4 h
after injection (Fig-
ure 5A,C,D). Control non-
targeted NPs and saline
injections did not produce
any significant change in
tumor contrast after 4 h
(DT2 ~ 0.4%). Signal meas-
urements from the body T2-
w images showed a decrease
in the ratio of liver-to-brain
signal both with targeted
and control nontargeted
NPs, thus confirming the
accumulation of NPs in the
liver area (Figure S10C,D).
To corroborate the MRI findings, the animals were euthan-
ized after imaging and their organs harvested and analyzed
for Fe content (Figure 5B). The amount of Fe in the tumors of
animals injected with the complete NPs was nearly double
that found with nontargeted NPs or the nontreated controls.
More interestingly, the Fe concentration values for the
individual animals correlated well with the decrease in
signal from the T2 maps (Figure S11A). An increased
amount of Fe in organs such as the liver and spleen was also
detected, an effect that is typically observed following the
administration of IONP contrast agents.[21] This increase was
more evident when nontargeted NPs were used, a result
attributed to the fact that targeted NPs were more efficiently
retained within the tumors (Figure S11B).
Harvested mouse organs were also used for histological
studies after imaging. Staining of the tissues revealed no
abnormal pathology of the organs when NPs were injected
(Figure S12). After proving aggregation in vitro (Figure 4),
a number of in vivo control studies were carried out to
ascertain the selectivity of the targeting moiety and of the
self-assembly mechanism of Fe accumulation within the
tumors. The results (Figure S13) show a significant difference
in Fe concentration in tumor between nontreated animals and
any of the treated animals (at least a 50% decrease in Fe
concentration in the treated animals; “treated”= inhibitor
injection for three days prior to NP contrast agent injection,
“non-treated”=NP contrast agent injection only). Both the
inhibition of CXCR4 and the inhibition of MMP enzymes
decreased the Fe concentrations in the tumors, after the
injection of the IONPs, to levels equal to or lower than those
of animals in which no contrast agent was injected. Histology
of these tumoral tissues further supports these findings
(Figure S14). Prussian blue staining for Fe deposits showed
Figure 3. Molecular structures of the final NP (12) and controls; 10=nontargeted NP (“azide family”),
13=NP without self-assembling properties (“azide family”).
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the presence of localized increased Fe concentration in
tumors of nontreated mice (with sizes up to ca. 10 mm),
while in the treated animals, Fe was scarce. These results show
that, as proposed, the decrease in MRI signal detected with
our probes comes from the combination of a targeted strategy
and the response of the probes to MMP enzymes.
Given that our NP system detects both MMP and CXCR4
expression, we have been careful to design the system to
reduce pharmacokinetic differences between different sets of
particles. We acknowledge that systemic co-administration of
a set of NPs could introduce co-delivery issues and that, for
our approach to be successful, both of the NPs have to
distribute to the target equally well. Notably, some of the
parameters that are commonly accepted to have a large
influence on biodistribution and circulation, for example, size,
shape, and surface charge, are very similar for both families of
NPs. It can thus be predicted that the particles will show
similar behavior when injected in vivo. Nevertheless, poten-
tially different abilities to reach the tumor cannot be
completely excluded.
In conclusion, novel IONPs bearing complementary azide
and alkyne click moieties were nanoengineered to undergo
copper-free [3+2] cycloaddition following MMP cleavage.
This effect was supported by T2 signal enhancement through
cluster formation. This work demonstrates the potential of
CXCR4 targeting together with MMP triggers and cyclo-
addition chemistry for enabling the production of efficient
and more sensitive cancer MRI in vivo. The work presented
shows that more complex NP designs can be used to confer
added value on probes. In this case, we have focused on
a current limitation of MRI technology, namely sensitivity,
but the design can also be extrapolated to other applications,
such as drug/gene delivery and targeted/triggered disease
treatment. We have demonstrated that more complex design
and synthesis can be carried out on NPs with relative ease to
enhance their effects both in vitro and in vivo and to elicit an
in situ response. This work should pave the way towards the
development of further “smart” targeted nanoparticles and,
by extension, nanomedicines for a variety of diseases.
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Figure 4. A) Hydrodynamic size measurements. Blue=1:1 mixture of
alkyne and azide NPs. Red=1:1 mixture of the alkyne and azide NPs
in the presence of hrMMP9. Purple=alkyne NPs in the presence of
hrMMP9. Green=azide NPs in the presence of hrMMP9. B) T2 values
obtained from U87.CD4.CXCR4 cells embedded in 1% agarose gels
incubated with a 1:1 mixture of the NPs (50 mg Fe/mL) for different
time periods (15, 30, and 60 min), either alone or in the presence
exogenous MMP9 or the CXCR4 inhibitor AMD3100 (30 min). C) DR2/
R2 cell values obtained from either U87.CD4.CXCR4 (CXCR4+) or
U87.CD4 (CXCR4-) cells incubated with a 1:1 mixture of the NPs
(50 mg Fe/mL; either final probe or controls, see Figure 3) for 30 min.
The results are given as the mean of three independent experiments 
the standard deviation.
Figure 5. A) Results from the analyses of T2 maps from a series of spin
echo images acquired with different TEs. Only the region of interest
comprising the tumor was considered for the analyses. B) Iron concen-
trations in the different organs measured 48 h after the injection of
targeted NPs. The results are expressed as the mean of three
independent experiments  the standard deviation. *= statistically
different with p<0.05, S. Int=small intestine, L. Int= large intestine.
Representative tumor T2 maps are shown from a series of spin echo
images acquired with different TEs before (C) and 4 h after (D) the
intravenous injection of targeted NPs. Color bar scale in milliseconds.
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